Glass articles with mixed polymer and metal oxide coatings

Abstract

According to one or more embodiments, a pharmaceutical package may include a glass container and a coating. The glass container may include a first surface and a second surface opposite the first surface. The first surface may be an outer surface of the glass container. The coating may be positioned over at least a portion of the first surface of the glass container. The coating may include one or more polyimide compositions and one or more metal oxide compositions. The one or more polyimide compositions and the one or more metal oxide compositions may be mixed in the coating.

What is claimed is: 
     
         1 . A pharmaceutical package comprising:
 a glass container comprising a first surface and a second surface opposite the first surface, wherein the first surface is an outer surface of the glass container; and   a coating positioned over at least a portion of the first surface of the glass container, the coating comprising:   one or more polyimide compositions; and   one or more metal oxide compositions;   wherein the one or more polyimide compositions and the one or more metal oxide compositions are mixed in the coating.   
     
     
         2 . The pharmaceutical package of  claim 1 , wherein a weight ratio of the one or more metal oxide compositions to the one or more polyimide compositions is from about 20/80 to about 95/5. 
     
     
         3 . The pharmaceutical package of  claim 1 , wherein a total amount of the one or more metal oxide compositions in the coating is from about 20 wt. % to about 95 wt. %. 
     
     
         4 . The pharmaceutical package of  claim 1 , wherein a total amount of the one or more polyimide compositions in the coating is from about 5 wt. % to about 80 wt. %. 
     
     
         5 . The pharmaceutical package of  claim 1 , wherein a combination of polyimides and metal oxides in the coating comprises at least about 50 wt. % of the coating. 
     
     
         6 . The pharmaceutical package of  claim 1 , wherein at least one of the one or more metal oxide compositions is zirconia, alumina, or titania. 
     
     
         7 . The pharmaceutical package of  claim 1 , wherein the coating has a thickness of 100 nm or less. 
     
     
         8 . The pharmaceutical package of  claim 1 , wherein the one or more polyimide compositions is fluorinated. 
     
     
         9 . The pharmaceutical package of  claim 1 , wherein the coating is bonded to at least a portion of the first surface of the glass container. 
     
     
         10 . The pharmaceutical package of  claim 1 , wherein the portion of the first surface of the glass container with the coating has a coefficient of friction of less than or equal to about 0.7. 
     
     
         11 . The pharmaceutical package of  claim 10 , wherein the portion of the first surface of the glass container with the coating retains the coefficient of friction of less than or equal to about 0.7 following a heat treatment at a temperature of at least about 250° C. for 30 minutes. 
     
     
         12 . The pharmaceutical package of  claim 1 , wherein a light transmission through the pharmaceutical package is greater than or equal to about 55% of a light transmission through an uncoated pharmaceutical package for each wavelength from about 400 nm to about 700 nm. 
     
     
         13 . The pharmaceutical package of  claim 12 , wherein the pharmaceutical package retains the light transmission through the pharmaceutical package of greater than or equal to about 55% of the light transmission through the uncoated pharmaceutical package for each wavelength from about 400 nm to about 700 nm following a heat treatment at a temperature of at least about 250° C. for 30 minutes. 
     
     
         14 . The pharmaceutical package of  claim 1 , wherein a weight ratio of the one or more metal oxide compositions to the one or more polyimide compositions is 90:10 or greater. 
     
     
         15 . The pharmaceutical package of  claim 1 , wherein a weight ratio of the one or more metal oxide compositions to the one or more polyimide compositions is about 35/65 or greater. 
     
     
         16 . The pharmaceutical package of  claim 1 , wherein a weight ratio of the one or more metal oxide compositions to the one or more polyimide compositions is about 50/50 or greater. 
     
     
         17 . The pharmaceutical package of  claim 1 , wherein a weight ratio of the one or more metal oxide compositions to the one or more polyimide compositions is about 75/25 or greater. 
     
     
         18 . The pharmaceutical package of  claim 1 , wherein a combination of polyimides and metal oxides in the coating comprises at least about 90 wt. % of the coating. 
     
     
         19 . The pharmaceutical package of  claim 1 , wherein a combination of polyimides and metal oxides in the coating comprises at least about 95 wt. % of the coating. 
     
     
         20 . The pharmaceutical package of  claim 1 , wherein a combination of polyimides and metal oxides in the coating comprises at least about 99 wt. % of the coating. 
     
     
         21 . A method producing a pharmaceutical package, the method comprising:
 depositing a coating mixture onto a first surface of an outer surface of a glass container, the coating mixture comprising:
 one or more metal oxide precursors; and 
 one or more polymer compositions, one or more polymer precursors, or both; and 
   heating the coating mixture to form a coating on the outer surface of the glass container, the coating comprising:
 one or more polymer compositions; and 
 one or more metal oxide compositions. 
   
     
     
         22 . The method of  claim 21 , wherein at least one metal oxide precursor is chosen from a titanate, a zirconate, a zirconium aluminate, an aluminate, or a hydrolysate or oligomer thereof. 
     
     
         23 . The method of  claim 21 , wherein at least one metal oxide precursor is chosen from a tetra-ortho-titanate, a hexa-coordinate chelated titanate, a polymeric titanate, or a hydrolysate or oligomer thereof. 
     
     
         24 . The method of  claim 21 , wherein at least one metal oxide precursor is a tetra-ortho-titanate or hydrolysate or oligomer thereof chosen from tetraethyl orthotitanate; tetramethyl orthotitanate; tetraisopropyl orthotitanate; tetrapentyl orthotitanate; tetraoctyl orthotitanate; tetradodecyl orthotitanate; tetra-2-ethylhexyl orthotitanate; tetrabenzyl orthotitanate; tetracyclohexyl orthotitanate; tetraphenyl orthotitanate; tetraethoxyethyl orthotitanate; tetra-n-butyl titanate; tetrakis(2-ethylhexyl)titanate; tetra-beta-naphthyl ortho-titanate; or hydrolysate or oligomer thereof. 
     
     
         25 . The method of  claim 21 , wherein at least one metal oxide precursor is a hexa-coordinate chelated titanate hydrolysate or oligomer thereof chosen from titanium acetylacetonate; diisopropoxytitanium bis(acetylacetonate); titanium acetylacetonate bis(pentane-2, 4-dionato-O, O′)bis(alkanolato)titanium; diisopropoxy-bis ethylacetoacetato titanate; Titanium(IV) (triethanolaminato)isopropoxide; or a hydrolysate or oligomer thereof. 
     
     
         26 . The method of  claim 21 , wherein at least one metal oxide precursor is a zirconium-containing metal oxide precursor. 
     
     
         27 . The method of  claim 26 , wherein the zirconium-containing metal oxide precursor is chosen from zirconium acetylacetonate; zirconium-tert-butoxide; zirconium hexafluoroacetylacetonate; zirconium naphthenate; zirconium propoxide; zirconium isopropoxide; zircon aluminates; tetra (2,2 diallyloxymethyl)butyl, di(ditridecyl)phosphito zirconate; neopentyl(diallyl) oxy,trineodecanoyl zirconate; neopentyl(diallyl) oxy,tri(dodecyl)benzene-sulfony zirconate; neopentyl(diallyl)oxy,tri(dioctyl)phosphato zirconate; neopentyl(diallyl)oxy,tri(dioctyl)-pyrophosphato zirconate; neopentyl(diallyl)oxy,tri(N-ethylenediamino)ethyl zirconate; neopentyl(diallyl)oxy,tri(m-amino)phenyl zirconate; neopentyl(diallyl)oxy,trimethacryl zirconate; neopentyl(diallyl)oxy,triacryl zirconate; dineopentyl(diallyl)oxy,diparamino benzoyl zirconate; dineopentyl(diallyl)oxy,di(3-mercapto)propionic zirconate); or a hydrolysate or oligomer thereof. 
     
     
         28 . The method of  claim 21 , wherein at least one metal oxide precursor is a tetra-coordinate aluminate metal oxide precursor. 
     
     
         29 . A pharmaceutical package comprising:
 a glass container comprising a first surface and a second surface opposite the first surface, wherein the first surface is an outer surface of the glass container; and   a coating positioned over at least a portion of the first surface of the glass container, the coating comprising:   one or more polymer compositions; and   one or more metal oxide compositions;   wherein the one or more polymer compositions and the one or more metal oxide compositions are mixed in the coating;   wherein a weight ratio of the one or more metal oxide compositions to the one or more polymer compositions is from about 20/80 to about 95/5; and   wherein a combination of polymers and metal oxides in the coating comprises at least about 95 wt. % of the coating.   
     
     
         30 . The pharmaceutical package of  claim 29 , wherein one or more of the one or more polymer compositions are polyimides.